PTC-209 HBr is a potent and selective BMI-1 inhibitor (IC50 = 0.5 μM) that irreversibly reduces cancer-initiating cells (CICs); it suppresses BMI-1-dependent tumor cell growth in colorectal cancer; inhibits UTR-mediated reporter gene expression and endogenous BMI-1 expression in human colorectal HCT116 and fibrosarcoma HT1080 cells in vitro; effectively inhibits BMI-1 production in tumor tissues and halts tumor growth in mouse xenograft models of primary human colorectal cancer, LIM1215, or HCT116 cells in vivo; reduces the frequency of functional colorectal cancer CICs in vivo; targets the BMI-1 self-renewal pathway.